Precision's Schafer in Drug Topics: The Future of Oncology Treatment Is Value Assessment


In this month’s Drug Topics, correspondent Kathleen Gannon Longo talks with Precision for Value’s Jeremy Schafer on the potentially tremendous impact that value assessments will have on future patient reimbursement decisions. Focusing on oncology treatment, Schafer describes some of the existing value frameworks, including Drug Abacus and ICER, as well as newer, more transparent frameworks emerging, such as the Innovation and Value Initiative (IVI).

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.